| David Mullens, DPM | |
|
1101 Welch Rd, Ste C6, Palo Alto, CA 94304 | |
| (650) 324-2091 | |
| (650) 324-4404 |
| Full Name | David Mullens |
|---|---|
| Gender | Male |
| Speciality | Podiatrist |
| Location | 1101 Welch Rd, Palo Alto, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1639139959 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213E00000X | Podiatrist | E1418 (Arkansas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| David Mullens, DPM 1101 Welch Rd, Ste C6, Palo Alto, CA 94304 Ph: (650) 324-2091 | David Mullens, DPM 1101 Welch Rd, Ste C6, Palo Alto, CA 94304 Ph: (650) 324-2091 |
News Archive
NeurOp, Inc., a biopharmaceutical company developing new treatments for central nervous system disorders, today announced that the National Institutes of Health (NIH) has awarded the company a $3 million grant to support its research program for ischemia.
As consumers begin to take greater ownership of their own healthcare, there is a growing demand for accessibility to diagnostic testing. Alverix, Inc. and BD (Becton, Dickinson and Company) are on the cutting edge of this trend and today announced an agreement to produce assay systems at the point-of-care (POC) that will improve infectious disease diagnoses.
People with a common form of hearing loss not helped by hearing aids achieved significant and sometimes profound improvements in their hearing and understanding of speech with hybrid cochlear implant devices, according to a new multicenter study led by specialists at NYU Langone Medical Center.
Sinovac Biotech Ltd. (NYSE: SVA), a leading provider of biopharmaceutical products in China, announced today that the Ministry of Industry and Information Technology of the People's Republic of China has issued the initial order to Sinovac to purchase H1N1 vaccine for the national stockpiling plan.
Hospitalized patients with community-acquired pneumonia (CAP) who received treatment regimens against atypical disease-causing pathogens reached clinical stability quicker, had fewer days of hospitalization, and had lower mortality rates as a result of their disease, according to a large new study.
› Verified 6 days ago
Elizabeth Anne Reilly, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 300 Pasteur Dr, Palo Alto, CA 94305 Phone: 650-723-4000 | |
Jonathan Jeah Seun, DPM Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 3801 Miranda Ave, Palo Alto, CA 94304 Phone: 650-493-5000 | |
Dr. Sandra Jay Loving, DPM Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 3801 Miranda Ave, Palo Alto, CA 94304 Phone: 650-493-5000 | |
Dr. Eghosa Isa, DPM Podiatrist Medicare: Medicare Enrolled Practice Location: 795 El Camino Real, Palo Alto, CA 94301 Phone: 650-853-2943 | |
Dr. Nancy Vilaysak Kim, DPM Podiatrist Medicare: Medicare Enrolled Practice Location: 3801 Miranda Ave, Palo Alto, CA 94304 Phone: 650-493-5000 | |
Aaron Z Handa, DPM Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 3801 Miranda Ave, Palo Alto, CA 94304 Phone: 650-493-5000 | |
Francis Dinh, Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 3801 Miranda Ave, Palo Alto, CA 94304 Phone: 650-493-5000 |